Enhanced Screening with AFP

The highest detection rate available in a first trimester
biochemical screening test is now better than ever.

Eurofins NTD, LLC. FirstTrimesterScreen | Fß test, which features the highest detection rate for Down syndrome available in a first trimester biochemical screening, is now enhanced with the addition of AFP. See Figure 1 for detection rates, false positive rates and other important specifications for FirstTrimesterScreen | Fß and SequentialScreen | Fß.

In addition to Down syndrome (trisomy 21), Eurofins NTD, LLC. screening tests continue to provide high detection rates for the common aneuploidies trisomies 18 and 13, and offer valuable information regarding other potential adverse pregnancy outcomes such as preeclampsia, low birth weight, preterm delivery and fetal loss.*

Learn more: new webinar

Learn more about how the AFP marker improves the first trimester screen detection rate for Down syndrome by viewing a new webinar hosted by Terrence W. Hallahan, PhD, Director of Eurofins NTD, LLC. You'll discover how enhanced screening gives you and your patients early assurance and more time to assess options for the best possible care.

Figure 1. Test Specifications

  FirstTrimester Screening Sequential Screening


free beta hCG, PAPP–A, AFP, Nuchal translucency (NT), (Nasal bone – NB)

First trimester: free beta hCG, PAPP–A, AFP, Nuchal translucency (NT)
Second trimester: AFP, free beta hCG, uE3, inhibin–A

What does it detect?

Trisomy 21, 18, 13

Trisomy 21, 18, 13, Open Neural Tube defects (ONTDs)

Detection rates

T21 – 93%1,2, 96% with Nasal bone1,2
T18/13 – 95%3

T21 – 95%2, 98% with Nasal bone2
T18/13 – 95%3
Spina bifida – 90%4
Anencephaly – 98%4

False positive rates (FPRs) for the conditions it detects

T21 – 5%1,2, 2% with Nasal bone1,2
T18/13 – 0.3%3

T21 – 5.8%2, 2.9% with Nasal bone2
T18/13 – 0.3%3

Gestational age when performed

Blood sample: 9–13 weeks, 6 days
NT: 11–13 weeks, 6 days

First trimester: Blood sample: 9–13 weeks, 6 days
NT: 11–13 weeks, 6 days
Second trimester: 15–21 weeks, 6 days

Turnaround Time

1–2 days

1–2 days

No Test Rate**



Failure rate***



Patient population
validated for testing

Low and high risk5

Low and high risk5

* Risks for these conditions may not be quantified in screening result reports
** No Test rate = samples not tested due to insufficient quality or quantity
*** Failure rate = samples processed but results could not be obtained

1. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol. 2006;194(1):127-130. 2. Data on file. Eurofins NTD, LLC. 3. Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free Fß-hCG and PAPP-A. Prenat Diagn. 2002;22(10):877-879. 4. Milunsky A, Jick SS, Bruell CL, et al. Predictive values, relative risks and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol. 1989;161(2):291-297. 5. ACOG practice bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109(1):217-227.

(References 60-90)